Farnesyltransferase (FTase) is a zinc enzyme that has been the subject of particular attention in anti-cancer research. Inhibitors of farnesyltransferase (FTase) have been designed for use as anti-Ras and anti-cancer…
The uPAR·uPA protein-protein interaction (PPI) is involved in signaling and proteolytic events. They promote tumor invasion and metastasis. Nearly every step of cancer metastasis, including cell migration, adhesion, angiogenesis, and invasion implicates…
TOPK (T–lymphokine-activated killer cell–originated protein kinase, also known as PBK or PDZ-binding kinase) is a Ser/Thr protein kinase. Many types of human cancer, including breast and lung cancers, highly expresses…
Sphingosine-1-phosphate ( S1P ), the bioactive sphingolipid metabolite, is a critical regulator of many physiological and pathophysiological processes, including cancer, atherosclerosis, diabetes and osteoporosis. S1P and its receptors (S1P1-5) play…
G protein-coupled receptors (GPCRs) exhibit a spectrum of functional behaviors in response to natural and synthetic ligands. Researchers generated the human β2 adrenergic receptor (β2AR) that exhibits G protein-like behavior.…
Tasisulam is an acyl sulfonamide with a unique antitumor dual mechanism of action. It involves antiangiogenesis and mitotic inhibition. Tasisulam has a broad range of activity in 60 tumor cell…
The proto-oncogene Myc belongs to the basic helix-loop-helix leucine zipper (B-HLH-LZ) transcription factor family. It plays a key role in cellular proliferation, differentiation, and apoptosis. Myc expression is normally under…
Bromodomain and extra-terminal (BET) family proteins include BRD2, BRD3, BRD4, and a testis-specific protein BRDT. In this study, researchers identify CD161. CD161 is a potent, orally bioavailable, and selective BET…
Ubiquitin-like with PHD and RING finger domains 1 (UHRF1) is a potent oncogenic protein. Its overexpression in various solid and blood tumors. Moreover, UHRF1 has an association with reduced expression…
Histone deacetylase (HDAC) inhibits are considered to be promising agents that can be used as treatments for cancer. CG-200745 is a novel and potent hydroxamate-based pan-HDAC inhibitor. CG-200745 has the…